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The aim of this study was to investigate the effect of the serine/threonine protein phosphatase inhibitor, calyculin-A (CLA), on
clot formation and on the procoagulant activity of human platelets. Platelet-rich plasma (PRP) samples were preincubated with
buffer or CLA and subsequently platelets were activated by the protease-activated receptor 1 (PAR-1) activator, thrombin receptor
activating peptide (TRAP). Clot retraction was detected by observing clot morphology up to 1 hour, phosphatidylserine- (PS-)
expression was studied by flow cytometry, and thrombin generation was measured by a fluorimetric assay. For the intracellular
Ca2+ assay, platelets were loaded with calcium-indicator dyes and the measurements were carried out using a ratiometric method
with real-time confocal microscopy. CLA preincubation inhibited clot retraction, PS-expression, and thrombin formation. TRAP
activation elicited Ca2+ response and PS-expression in a subset of platelets. The activated PRP displayed significantly faster and
enhanced thrombin generation compared to nonactivated samples. CLA pretreatment abrogated PS-exposure and clot retraction
also inTRAP-activated samples. As a consequence of the inhibitory effect on calciumelevation andPS-expression, CLA significantly
downregulated thrombin generation in PRP. Our results show that CLA pretreatment may be a useful tool to investigate platelet
activation mechanisms that contribute to clot formation and thrombin generation.
1. Introduction
Platelets play a crucial role in the pathogenesis of atheroscle-
rotic diseases including acute coronary syndrome or ischemic
stroke that are leading causes of death and disability world-
wide.These events are triggered by disruption of the endothe-
lium and plaque rupture or during interventions on coro-
naries, when platelets are tethered to surface-bound von
Willebrand Factor (vWF), which initiates platelet activation
and allows them to adhere to subendothelial components.
Protease-activated receptor 1 (PAR-1), the primary
platelet thrombin receptor, is G-protein-coupled. The acti-
vator of this receptor is the strongest platelet agonist and
an important contributor to atherothrombotic processes.
Modulation of the PAR-1 receptor is the target for novel
and promising antiplatelet drugs [1, 2]. PAR-1 receptor
activation via thrombin or relevant thrombin receptor
activating peptides (TRAPs) results in a series of signaling
events terminating in platelet shape change and granule
secretion via the G12/13 proteins and intracellular calcium
release via the Gq mediated inositol triphosphate (IP3)
pathway. Intracellular IP3 receptors can be directly activated
by pharmacological agents like thiomersal that has been
used previously as a calcium mobilizer and cell function-
modulating agent [3].
Serine/threonine protein phosphatases (PP) are present
in platelets predominantly as type 1 protein phosphatase
(PP1) and type 2A protein phosphatase (PP2A) subtypes.
Calyculin-A (CLA), a naturally occurring phosphatase
inhibitor, present in marine sponges, in nanomolar concen-
tration, primarily inhibits PP2A and indirectly PP1 [4, 5].
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Among the other frequently used PP inhibitors tautomycetin
selectively inhibits PP1, while okadaic acid at nanomolar
concentrations preferentially suppresses the activity of PP2A
[6–8]. Both PP1 and PP2A can be found in themembrane and
cytosolic fractions of resting platelets [9].
A previous study from our group has described the effects
of calyculin-A onTRAP-stimulated human platelets [8] and it
was concluded that phosphatase inhibition prevents platelet-
derived microparticle (MP) formation and degranulation in
TRAP-activated platelets.
Surface exposure of phosphatidylserine (PS) is increased
during platelet activation or apoptosis [10] and PS-expression
is a key event in the control of blood coagulation, localizing
prothrombin activation to the platelet plug, and regulating
thrombin generation [11]. The initiation of early platelet
activation events such as Ca2+-influx can also be affected
by CLA, which blocks any further propagation of platelet
reactivity [12].
The aim of this study was to explore the effects of CLA
on resting and activated platelets and to simultaneously
investigate clot formation, platelet activation, and thrombin
generation and their modulation in platelet-rich plasma. PS-
expression, intracellular calcium responses using a novel
cytosolic Ca2+ levelmeasurement, clot retraction, and throm-
bin generationwere studiedwith orwithout TRAP activation.
We show here, for the first time, that in platelet-rich plasma
CLA blocked clot retraction and inhibited cytosolic Ca2+ ele-
vation upstream of the IP3 receptor, abolished PS-expression,
and subsequently inhibited thrombin generation. Thus, we
suggest that this phosphatase inhibitor can be utilized in
a wide variety of platelet functional assays for exploring
biochemical pathways during thrombus formation.
2. Materials and Methods
2.1. Antibodies and Reagents. For flow cytometric analysis
of PS-exposure we used FITC-labeled Annexin-V, Annexin-
V binding buffer (10x concentrate), from Becton Dickin-
son (San Jose, CA), and a monoclonal anti-human CD41-
PE antibody from Dako (Glostrup, Denmark). For platelet
preparation either for flow cytometry or for the thrombin
generation assay or intracellular Ca2+ measurements we used
the following materials: paraformaldehyde (PFA), dimethyl-
sulfoxide (DMSO), bovine serum albumin (BSA), HEPES,
apyrase from potato, and Arg-Gly-Asp-Ser (RGDS) which
were obtained from Sigma-Aldrich (St Louis, MO).
We used thrombin receptor activating peptide (TRAP)
and thiomersal fromSigma-Aldrich (St Louis,MO) as platelet
agonists. The protein phosphatase inhibitor, CLA, was from
Calbiochem (San Diego, CA). HEPES buffer for flow cytom-
etry and thrombin generation methods contained 150mM
NaCl and 25mM HEPES, pH 7.4. HEPES-buffered saline
for intracellular Ca2+ level measurements contained 145mM
NaCl, 10mM HEPES, 10mM D-glucose, and 5mM KCl,
pH 7.4, supplemented with 0.1% (w/v) BSA, 100𝜇M RGDS,
200𝜇MCaCl2, and 0.1 U/mL apyrase. For some experiments
during the analysis of free calcium levels instead of CaCl2 the
previously described HEPES buffer was supplemented with
500 𝜇M ethylene glycol-bis(2-aminoethylether)-N,N,N󸀠,N󸀠-
tetraacetic acid (EGTA) from Sigma-Aldrich (St Louis, MO).
We shall refer to this buffer hereafter as Ca2+-free buffer.
2.2. Preparation of Platelet-Rich Plasma. Whole blood was
drawn from healthy volunteers with no medications for at
least 2 weeks prior to the experiments. Blood sample collec-
tion from volunteers was approved by the Ethical Committee
of the University of Debrecen. The DEOEC RKEB/IKEB
4318-2015 protocol grants permission to draw citrated blood
samples from patients and controls both for analysing plasma
and platelets. Blood was anticoagulated with 0.105M sodium
citrate. Platelet-rich plasma (PRP) was prepared from venous
whole blood by centrifugation at 170×g for 15 minutes at
room temperature (RT). Platelet count of PRP was adjusted
to 250G/L by adding platelet poor plasma (PPP). PPP was
obtained by centrifugation of the citrated blood sample at
1500×g for 15 minutes at RT. In subsequent experiments the
following PRP samples were analysed: (i) nonactivated (NA),
(ii) CLA-pretreated nonactivated (NA + CLA), (iii) TRAP-
activated (TRAP), and (iv) CLA-pretreated TRAP-activated
(TRAP + CLA). In preliminary experiments 50 nM CLA was
found to inhibit degranulation of platelets as well as PAC-1
binding without being toxic to cells so this concentration of
CLAwas applied in the experiments. TRAPwas used at a final
concentration of 20𝜇M.
2.3. Clot Retraction Analysis. PRP (720𝜇L) was preincubated
with buffer control or CLA for 30 minutes at 37∘C in a
water bath and then activated by TRAP. In a glass tube,
800 𝜇L of every four samples was incubated with CaCl2 (at
a final concentration of 25mM) for 60 minutes at 37∘C in
a water bath. At time points 0, 20, 40, and 60 minutes,
photos were taken to document clot formation. At the end
of the experiment, the volume of the extruded serum was
determined by an analytical scale. The amount of fibrin
monomer in the extruded serum was measured by a latex
enhanced quantitative immunoassay (Stago, Asnie´re, France)
on the ACL-TOP coagulation analyser (Instrumentation
Laboratory, Bedford, MA).
2.4. Flow Cytometric Assays. PRP (110 𝜇L) was preincubated
with either HEPES buffer containing 0.5% DMSO as control
or the protein phosphatase inhibitor CLA, for 30 minutes at
37∘C in a water bath. CLA was used at a final concentration
of 50 nM. After preincubation, platelets were activated either
by TRAP at a final concentration of 20 𝜇M or by thiom-
ersal at a final concentration of 200𝜇M for 15 minutes at
37∘C in a water bath. Then PRP (5 𝜇L) was stained with
5 𝜇L monoclonal CD41-PE antibody and 5 𝜇L Annexin-V-
FITC and Annexin-V binding buffer (1x concentrate) was
added to examine the PS-expression of the platelets. In each
experiment 10,000 events were collected in the platelet gate,
measured by an FC500 flow cytometer, and results were
analysed with the Kaluza software (Beckman Coulter, CA).
2.5. Thrombin Generation Assay. Eighty microliters of pre-
treated PRP was incubated with 20𝜇L of standard prepara-
tions of 1 pM recombinant tissue factor (rTF, PRP-Reagent,
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Thrombinoscope BV, Maastricht, The Netherlands) for 10
minutes in round-bottomed 96-well black microplates. For
each PRP sample a simultaneously run calibrator, a sta-
ble complex of 𝛼2-macroglobulin (𝛼2M) and thrombin
(Calibrator-Reagent, Thrombinoscope BV, Maastricht, The
Netherlands), was used to eliminate the differences between
samples [13]. Thrombin generation was initiated by the
addition of 20𝜇L of a mixture of fluorogenic substrate
and Fluo-Buffer that contained CaCl2 (Thrombinoscope BV,
Maastricht, The Netherlands). Fluorescence was detected
by a Fluoroskan Ascent fluorimeter (Helsinki, Finland)
and the thrombin generation curves were analysed by the
Thrombinoscope software (Thrombinoscope BV, Maastricht,
The Netherlands). Thrombin generation curves were charac-
terised by the following parameters (calculated and presented
by the Thrombinoscope software): Lagtime is the delay in
minutes until thrombin formation starts. Peak thrombin
expressed in nanomoles is the highest thrombin level and the
time required to reach the peak thrombin level is designated
as time to peak (in minutes). Velocity index (in nanomoles
per minute) is the slope between lagtime and time to peak.
2.6. High-Speed Confocal Measurement of Platelet Cytosolic
Ca2+ Levels. For measurements of intracellular Ca2+ levels,
PRP was prepared as described above and RGDS peptide
was added to prevent aggregation [14]. PRP (100 𝜇L) was
loaded with 1.5𝜇L of 2mMFluo-4-AM for 10minutes at 37∘C
in a water bath. The cells were coloaded with Fura-Red by
addition of 2𝜇L of 1mM Fura-Red-AM for 30 minutes at
37∘C in a water bath. Before centrifugation, 2mL of HEPES-
buffered saline was added and after centrifugation at 350×g
for 20minutes at RT, the coloaded platelets were collected and
resuspended in 100 𝜇L of the same buffer.
Platelets loaded with the calcium-indicator dyes were
imaged using a Zeiss LSM 5 LIVE (Carl Zeiss AG, Jena,
Germany) high-speed confocal scanning unit with a 40x oil
immersion objective (NA: 1.3). The final 100𝜇L solution was
pipetted onto a glass coverslip secured above the objective
within a temperature-controlled chamber and was allowed
to rest for 2 minutes before the measurement. Both the
chamber and the objective had been preheated to 37∘C and
this temperature was kept constant during the measurement.
Frames (𝑥-𝑦 images) were recorded at a rate of 5Hz for
5 minutes using 488 nm excitation wavelength and two
detection channels: a band pass filtered channel between 500
and 525 nm for the Fluo-4 signal and a long pass filtered
channel above 635 nm for the Fura-Red signal. The wide
gap between the cutoff wavelengths ensured that there was
minimal crosstalk between the channels.
Details of the ratiometric method are demonstrated in
Supplementary Figure 1 in Supplementary Material avail-
able online at https://doi.org/10.1155/2017/9795271. The green
(Figures S1A, S1D, and S1G) and red (Figures S1B, S1E,
and S1H) fluorescence channels were measured separately;
then composite images were formed where color changes
from red to green indicated increased intracellular Ca2+
concentrations (Figures S1C, S1F, and S1I). All platelets that
could be observed for at least 30 s before and 90 s after
the addition of TRAP were manually marked as regions of
interest (ROIs) on the recorded image series. Time series
curves of fluorescence values were analysed using a custom-
built computer program. The average fluorescence level
within a ROI on each channel was determined for all frames
(𝐹Fluo-4, green, and 𝐹Fura-Red, red; Figures S1J and S1M).
Exponential fitting was used to determine the baseline fluo-
rescence intensity on each channel (𝐹0(Fluo-4) and 𝐹0(Fura-Red))
taking into account the different bleaching levels for the
two dyes during the experiment. Relative fluorescence values
for the Fluo-4 (𝐹󸀠Fluo-4, green) and Fura-Red (𝐹
󸀠
Fura-Red,
red) channels were calculated from the original fluores-
cence values by normalization to the respective baseline
fluorescence curve (Figures S1K and S1N). Fluorescence ratio
(𝐹󸀠Fluo-4/𝐹
󸀠
Fura-Red, blue) values corresponding to the intra-
cellular Ca2+ level in the platelet were calculated by dividing
the relative fluorescence value for the Fluo-4 channel by that
of the Fura-Red channel at every time point (Figures S1L
and S1O). Calcium transients, but not nonspecific changes
of fluorescence intensity, are characterised by a simultaneous
negative deflection of the 𝐹󸀠Fura-Red and positive deflection
of the 𝐹󸀠Fluo-4 curves and thus the 𝐹
󸀠
Fluo-4/𝐹
󸀠
Fura-Red trace.
The magnitude of the transients can be characterised by the
amplitude measured on the fluorescence ratio curve.
TRAPwas added by pipetting 4 𝜇L of 500𝜇MTRAP solu-
tion to the platelet suspension on the coverslip. Measurement
was continuous during the addition of TRAP.
2.7. Statistical Analysis. Normality of the data was evaluated
by the Kolmogorov-Smirnov test. Data are expressed asmean
± SD or mean ± SEM. Predetermined pairwise differences
were analysed by paired Student’s 𝑡-test and 𝑝 values less
than 0.05 were considered as statistically significant. In case
the data showed a nonnormal distribution, the Wilcoxon
signed rank-sum test was used for statistical evaluation. 95%
confidence intervals for proportions were calculated using
the modified Wald method.
3. Results
3.1.The Effect of CLA on Clot Retraction. It could be observed
that clot formation and retraction commenced already by
20 minutes and by 60 minutes both the nonactivated and
the TRAP-activated samples displayed an intense clot retrac-
tion. The CLA-pretreated samples however were much less
retracted (Figure 1(a)). In accordance with this morphology
theCLA-pretreated samples extruded significantly less serum
(Figure 1(b)). The fibrinogen concentration was unmeasur-
ably low in the samples by 60 minutes; nevertheless the fibrin
monomers (FM) were determined by a quantitative assay and
it was found that in the extruded sera of CLA-pretreated
samples there was a tendency to higher FM values compared
to nonpretreated samples (Figure 1(c)).
3.2. The Effect of CLA on the Level of Platelet PS-Expression.
In a series of experiments we determined the level of PS-
exposure to analyse the effects of CLA on resting and acti-
vated platelets. PRP samples were preincubated with HEPES
buffer (control) containing 0.5% DMSO or 50 nM CLA in
DMSO for 30 minutes. Platelets were identified according to
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Figure 1: Inhibitory effect of CLA on clot retraction. Nonactivated (NA) and TRAP-activated samples displayed an intense clot retraction by
60minutes, while CLA-pretreated samples were much less retracted (a).This significant difference could be observed by the lower quantity of
extruded serum in CLA-pretreated samples (b) and a tendency could be observed to display higher fibrin monomer concentrations in CLA-
pretreated samples (c). Nonactivated and activated samples are indicated with open bars and CLA-preincubated samples are represented by
the black bars.The results are the mean and standard error of the mean (SEM) of 5 different experiments. Statistical significance was assessed
by paired 𝑡-test. ∗∗𝑝 < 0.01. ns = nonsignificant.
their CD41-PE staining; then PS-expression was determined
by Annexin-V positivity. The PS-expression of nonactivated
(NA) samples (Figure 2) was low (mean ± SD = 3.03 ± 0.84)
and it was further decreased by CLA pretreatment (mean
± SD = 1.75 ± 0.67, 𝑝 = 0.004). The PAR-1 receptor
agonist, TRAP, significantly increased the number of platelets
expressing PS (mean ± SD = 18.7 ± 3.23) compared to the
NA sample (𝑝 < 0.0001) while CLA pretreatment completely
prevented PS upregulation in TRAP-stimulated platelets (𝑝 <
0.0001) (Figure 2).
3.3. The Effect of CLA on Various Thrombin Genera-
tion Parameters. Representative thrombin generation curves
demonstrate the effect of TRAP and/or CLA on thrombin
formation by platelets (Figure 3(a)).The thrombin formation
was faster, and the lagtime and time to peak were shorter
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Table 1: Proportion of platelets responding to activation by TRAP.
Sample Total number of investigatedplatelets
Ca2+ transient in response to
activation by TRAP No transient change
𝑛 % 𝑛 %
TRAP-activated PRP 117 26 22.2%(15.59–30.62%) 91
77.8%
(69.38–84.41%)
CLA-preincubated
TRAP-activated PRP 122 0 (0.0–3.67%) 122
100%
(96.33–100.0%)
Numbers in brackets indicate the 95% confidence interval; total number of samples = 13 for each dataset.
40
35
30
25
20
15
10
5
0
PS
-e
xp
re
ss
io
n 
(%
)
NA TRAP
∗∗∗
∗∗∗
Figure 2: Inhibitory effect of CLA on PS-expression. Nonactivated
(NA) and activated samples are indicated with open bars and
CLA-pretreated samples with black bars. The results are the mean
and standard deviation (SD) of 8 different experiments. Statistical
significance was assessed by paired 𝑡-test. ∗∗∗𝑝 < 0.001.
in case of TRAP activation compared to the nonactivated
sample (Figures 3(b) and 3(c)). TRAPactivation increased the
peak thrombin and also the velocity index (Figures 3(d) and
3(e)). CLA preincubation significantly prolonged the time of
thrombin generation in TRAP-activated samples but did not
have significant effect on the NA sample. CLA attenuated the
peak thrombin and velocity index already in NA samples and
completely blocked the TRAP-elicited augmentation in these
parameters.
3.4. RatiometricMeasurement of Platelet Cytosolic Ca2+ Levels.
Platelets marked on confocal time series images were divided
into groups based on the time course and magnitude of
calcium transients during the experiment.
Platelet intracellular Ca2+ levels were measured after acti-
vation of nonactivated or CLA-pretreated sample. Two typi-
cal patterns of intracellular calcium concentration changes of
platelets were observed on TRAP-activated samples without
CLA pretreatment: no transient change after the addition
of TRAP (Figure 4(a)) or a transient increase in the Ca2+
level (Figure 4(b)). When platelets were preincubated with
CLA all calcium transients were abolished (Figure 4(c)). All
curves depict𝐹󸀠Fluo-4/𝐹
󸀠
Fura-Red valueswhere an increase indi-
cates higher cytosolic calcium levels. First, we investigated
nonactivated platelets for 60 seconds and TRAP was added
to the PRP during the microscopic measurement. Dotted
vertical lines mark the time of TRAP addition. One hundred
and seventeen platelets were investigated in TRAP-activated
samples. In the case of samples that were not pretreated,
22.2% of platelets showed transient cytosolic Ca2+ increase
upon TRAP addition. In case of platelets preincubated with
calyculin-A, none of the investigated 122 cells showed calcium
transients after TRAP administration during the time course
of the measurement providing evidence for CLA blockage
of Ca2+ elevation (Table 1). It is important to emphasize that
CLA pretreatment did not affect resting cytosolic calcium
levels (data not shown).
3.5. The Effect of Thiomersal on Platelet Activation. Both
nonactivated and CLA-preincubated samples were treated
with thiomersal at a final concentration of 200𝜇M and
PS-expression was determined by flow cytometry. The PS-
expression of nonactivated samples was 2.3% (Figure 5 (NA))
that was further decreased by CLA preincubation (Figure 5
(NA + CLA)). The ratio of PS-expressing cells was increased
to 16.4% by TRAP activation (Figure 5 (TRAP)) that could
be completely blocked by CLA. Contrary to the TRAP
activation, thiomersal activation induced 96% PS-expression
(Figure 5 (thiomersal)) that could not be prevented by CLA
preincubation (Figure 5 (thiomersal + CLA)).
Thiomersal evoked a prolonged elevation of cytosolic
calcium in all the platelets followed by sustained store-
operated calcium entry (Figure 6(a)). Nonactivated platelets
kept in calcium-free buffer show a minimal calcium entry
in response to the resupplement of extracellular calcium by
calcium chloride, probably due to platelets that were activated
by physical contact with the glass coverslip (Figure 6(b)).
In CLA-pretreated platelets thiomersal also evoked a pro-
longed elevation of cytosolic calcium followed by sustained
store-operated calcium entry, similarly to the response seen
in NA platelets (Figure 6(c)). All preparations responded to
calcium ionophore A23187 with increased calcium levels.
All curves are based on 𝐹󸀠Fluo-4/𝐹
󸀠
Fura-Red values where an
increase indicates higher cytosolic calcium levels.
4. Discussion
It is widely accepted that cell surface expressed, negatively
charged phospholipids are required for the formation of
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Figure 3: Thrombin generation assay and the effect of CLA on various parameters during thrombin generation. Thrombin generation in
PRP was investigated as a procoagulant function of the intracellular Ca2+ level changes. The dotted line corresponds to nonactivated sample,
the dashed line represents the CLA-pretreated nonactivated sample, black line marks the TRAP-activated sample, and CLA pretreatment on
TRAP-activated sample is represented by the grey line (a). Lagtime (b) and time to peak (c) values were observed during TRAP-elicited platelet
activation peak thrombin (d) and velocity index (e) values are informative about the amount and speed of generated thrombin. Nonactivated
and activated samples are indicated with open bars and CLA-preincubated samples with black bars. The results are the mean and standard
deviation (SD) of 5 different experiments. Statistical significance was assessed by paired 𝑡-test. ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001. ns = nonsignificant.
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Figure 4: Characteristic changes of the cytosolic Ca2+ level of single platelets in relation to TRAP activation. Three typical time courses of
the intracellular calcium concentration of platelets: no response to TRAP (a), transient increase in the Ca2+ level after the addition of TRAP
(b), and no transient change upon CLA pretreatment (c). All curves are 𝐹󸀠Fluo-4/𝐹
󸀠
Fura-Red values where an increase indicates higher cytosolic
calcium levels. Dotted lines mark the time of TRAP addition.
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Figure 5:The effects of TRAP, thiomersal activation, andCLApreincubation on phosphatidylserine-expression (PS).The positivity of platelet
PS-expression according to the Annexin-V labeling is in the upper right quadrants of the dot plots.The PS-expression of nonactivated sample
(NA) was very low. When platelets were preincubated with CLA the PS-expression further decreased. Representative dot plots show that
TRAP activation resulted in elevated PS-expression, which was completely blocked by preincubation with CLA.Thiomersal activated almost
all of the platelets and this activation could not be inhibited by CLA preincubation.
3.0
2.5
2.0
1.5
1.0
0.5
NA
Thiomersal CaCl2 A23187
0 100 200 300 400 500 600
Time (s)
F
㰀 F
lu
o
-4
/
F
㰀 F
u
ra
-R
ed
(a)
NA CaCl2 A23187
0 100 200 300 400 500 600
Time (s)
3.0
2.5
2.0
1.5
1.0
0.5
F
㰀 F
lu
o
-4
/
F
㰀 F
u
ra
-R
ed
(b)
CaCl2 A23187CLA-pretreated
Thiomersal
0 100 200 300 400 500 600
Time (s)
3.0
2.5
2.0
1.5
1.0
0.5
F
㰀 F
lu
o
-4
/
F
㰀 F
u
ra
-R
ed
(c)
Figure 6: Changes of the cytosolic Ca2+ level of platelet groups in relation to activation by thiomersal in Ca2+-free buffer and the consequent
store-operated calcium entry. Thiomersal evoked a prolonged elevation of cytosolic calcium in all the platelets followed by sustained store-
operated calcium entry (a). Nonactivated platelets kept in calcium-free buffer show a minimal calcium entry in response to the resupplement
of extracellular calcium by calcium chloride, probably due to platelets that got activated on physical contact to the glass coverslip (b).
Thiomersal evoked a prolonged elevation of cytosolic calcium in CLA-pretreated platelets followed by sustained store-operated calcium entry,
similarly to the response seen in NA platelets (c). All preparations responded to calcium ionophore A23187 with an increased calcium level.
All curves are 𝐹󸀠Fluo-4/𝐹
󸀠
Fura-Red values where an increase indicates higher cytosolic calcium levels. Arrows mark the addition of thiomersal.
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multiprotein complexes of the coagulation cascade. Thus,
this membrane dependency identified as PS-exposure can be
regarded as a cellular control of coagulation processes during
thrombus formation.
In our experiments we have investigated calcium signal-
ing and PS-expression of platelets and investigated the role
of phosphatase inhibition in these processes and subsequent
thrombin formation in nonactivated and PAR-1 activated
samples. Instead of thrombin we utilized TRAP, a potent
activator of PAR-1 on platelets, to avoid early clotting and any
potential pleiotropic effects [15].
Serine/threonine protein phosphatases play an essential
role in cellular signaling, metabolism, and cell cycle control
[7]. The activity of these phosphatases is needed for the initi-
ation of platelet secretion and aggregation that is evident from
the study which described that CLA suppressed aggregation,
adhesion, secretion, and platelet spreading on fibrinogen [16].
Under experimental conditions in phosphatase-inhib-
itor-treated platelets, actin polymerization was inhibited,
microtubules were reorganized in sustained pseudopods,
and the phosphorylation of myosin light chain (MLC) was
not enhanced upon thrombin stimulation [17]. The MLC
phosphorylation is crucial in actomyosin contraction for
platelet secretion, which is induced by MLC kinase and
counterbalanced bymyosin phosphatase including associated
protein phosphatase-1 catalytic subunit and myosin binding
(MBS/MYPT1) regulatory subunit [18].
When platelets are stimulated with thrombin, among
several intracellular proteins, Rho-kinase, PKC, and integrin-
linked kinase become activated resulting in the phosphoryla-
tion of MBS/MYPT1 (atThr695/Thr696) causing a decreased
myosin phosphatase activity accompanied with an elevated
MLC phosphorylation [19, 20]. This leads to actomyosin
contraction and subsequent secretion.
When CLA was added to platelets, PP was also blocked
in this complex and this intervention further increased the
phosphorylation of MYPT1 decreasing myosin phosphatase
activity [8]. Already 10 nM CLA decreased phosphatase
activity in both resting and TRAP-activated samples andwith
50 nM the control phosphatase activity was decreased by
more than 50%.Therefore, in the present studywe used a final
concentration of CLA of 50 nM.
Activation of platelets by various agonists is accompanied
by a transient intracellular Ca2+ elevation, which is obliga-
tory for the initiation and propagation of platelet responses
such as adhesion, aggregation, and degranulation. The rise
in intracellular calcium is a result of the calcium release
from the intracellular stores mediated by the IP3 receptor.
The depletion of the intracellular calcium stores is sensed
by stromal interaction molecule (STIM1). Consequently, a
calcium entry channelmolecule (Orai1) is activated by STIM1
and elicits store-operated calcium entry (SOCE).This STIM-
Orai regulated mechanism has been described in several cell
types including platelets [21].
In earlier studies, it was found that CLA treatment of
activated platelets suppressed the activation induced rise in
Ca2+ levels measured by fluorescence spectrophotometric
techniques [22, 23]. Experimental techniques have con-
siderably improved in the past decades. More recently, a
ratiometric flow cytometric method has been described that
is suitable for measuring calcium fluxes in platelets [24].
We have investigated platelet cytosolic Ca2+ levels by a real-
time ratiometric measurement with confocal microscopy,
to more appropriately characterise changes in intracellular
calcium signals. It was found that activating platelets by
TRAP via the PAR-1 receptor causes a clear intracellular
Ca2+ signal in a proportion of platelets that was abolished
by CLA pretreatment and this effect was unrelated to resting
calcium levels. In control samples, upon TRAP activation,
a heterogeneous response was predictable [25, 26]. Indeed,
we have observed two clear patterns: fast and robust Ca2+-
transients in 22% of platelets and no Ca2+-response in the
rest. Similar to the heterogeneity in calcium signals, not all
platelets express PS upon activation. After platelet activation,
these distinct platelet subpopulationsmay have different roles
in the coagulation process, depending on their activation
state and surface properties [27]. Similarly to calcium signals,
not all platelets express PS upon activation; there is current
evidence for platelet subpopulations, heterogeneity of platelet
responses, and functions in the thrombus-forming process
[28–30].We attribute the two distinct Ca2+-response patterns
to the existence of the above-mentioned platelet subpop-
ulations. Response heterogeneity can be due to intrinsic
differences between platelets in age and in receptor and
signaling proteins. As a result, at least three subpopulations
of platelets have been suggested in a thrombus: aggregating
platelets with (reversible) integrin activation, procoagulant
(coated) platelets exposing phosphatidylserine and binding
coagulation factors, and contracting platelets with cell-cell
contacts [28].
By using thiomersal, a direct activator of the intracellular
IP3 receptors, we could verify both by flow cytometric PS-
expression studies and by the ratiometric calcium measure-
ment that PP inhibition by CLA does not impair direct IP3
receptor stimulation, so its effect is exerted upstream of the
IP3 receptor.
The thrombin generation test was originally described for
plasma [31] and has later been extended to PRP [32] and it
was found that this test may reveal important interactions
between platelets and the clotting system [33]. In our exper-
iments the speed of thrombin generation as measured by
the lagtime and time to peak parameters and the activity of
generated thrombin as exemplified in the peak thrombin and
velocity index parameters were shown to be the most useful
parameters to evaluate the effect of CLA on the thrombin
generation of PRP.
Raised Ca2+ levels lead to the exposure of PS on the
platelet surface that serves as a site for the assembly of
intrinsic and extrinsic tenase and prothrombinase complexes;
thus it is critical for thrombin generation in PRP [34]. We
have found that CLA on TRAP-activated platelets influenced
platelet responses by eliminating calcium transients. It also
abolished agonist-induced PS-exposure and consequently
downregulated thrombin generation in PRP as demonstrated
both by the speed of thrombin formation and by the amount
of generated thrombin.
PS exposing platelets are procoagulant; however, they
are nonadhesive and possess closed (or blocked) integrins;
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thus they are unlikely to participate in clot retraction. Nev-
ertheless, in our experiments CLA also inhibited the platelet
subpopulation that participates in clot retraction. Fibrinogen
was clotted to insoluble fibrin so very little fibrin monomer
remained in the extruded serum particularly in the TRAP-
activated PRP. We have found that CLA attenuated thrombin
formation thatmay have contributed to less crosslinked fibrin
in the clot and thus more FM was detectable in the extruded
serum.
Taken together, these findings indicate that inhibition of
PP by CLA pretreatment can be regarded as a useful tool to
investigate the platelet subsets that contribute to enhanced
thrombin formation and clot retraction.
5. Conclusions
Calyculin-A effectively inhibits phosphatases in resting and
activated platelets and can be used in a wide variety of
platelet functional assays ranging from clot retraction, via
calcium measurements, to thrombin generation. With the
simultaneous use of selective platelet activators it can be
utilized to dissect biochemical pathways during thrombus
formation.
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